Advanced Search:
Equity Index

IPN.PA - IPSEN

€110.30  1.1 (1.01%)

Updated: 11:49 May 5, 2024 EST

Next Session's AI Forecast

99.32%

Avg. Accuracy (AI)

€112.46

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

€111.65

IPSEN's Position Within the Drug Manufacturers—Specialty & Generic Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

IPSEN - HISTORICAL DATA 6M

  • Last price

    €110.30

  • Daily change

    €1.1

  • Previous Close

    €109.2

  • Last Updated

    11:49 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.1 0.53 0.18 0.12 0.06

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.1 1.07 1.14 1.06 1.16

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 100% 100% 100%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
116.55 2.1% 114.15 3.11% 110.71 3.4% 107.07

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1.5 71.43 6.94 60

IPSEN Technical Analysis News

IPSEN

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Sectors: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
F. Time Employees: 5325
Description

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Corporate Governance

Ipsen S.A.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 7; Compensation: 7.

IPSEN'S HOLDERS RANK

List of holders with stock participation in IPSEN.

Holder Rank Holder Shares Date Reported % Out Value